Mosenzon, Ofri, Raz, Itamar, Wiviott, Stephen D, Schechter, Meir, Goodrich, Erica L, Yanuv, Ilan, Rozenberg, Aliza, Murphy, Sabina A, Zelniker, Thomas A, Langkilde, Anna Maria et al (show 11 more authors)
(2022)
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
DIABETES CARE, 45 (10).
pp. 2350-2359.
ISSN 0149-5992, 1935-5548
Abstract
<h4>Objective</h4>In patients with moderate to severe albuminuric kidney disease, sodium-glucose cotransporter 2 inhibitors reduce the risk of kidney disease progression. These post hoc analyses assess the effects of dapagliflozin on kidney function decline in patients with type 2 diabetes (T2D), focusing on populations with low kidney risk.<h4>Research design and methods</h4>In the Dapagliflozin Effect on Cardiovascular Events-Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial, patients with T2D at high cardiovascular risk were randomly assigned to dapagliflozin versus placebo. Outcomes were analyzed by treatment arms, overall, and by Kidney Disease: Improving Global Outcomes (KDIGO) risk categories. The prespecified kidney-specific composite outcome was a sustained decline ≥40% in the estimated glomerular filtration rate (eGFR) to <60 mL/min/1.73 m2, end-stage kidney disease, and kidney-related death. Other outcomes included incidence of categorical eGFR decline of different thresholds and chronic (6 month to 4 year) or total (baseline to 4 year) eGFR slopes.<h4>Results</h4>Most participants were in the low-moderate KDIGO risk categories (n = 15,201 [90.3%]). The hazard for the kidney-specific composite outcome was lower with dapagliflozin across all KDIGO risk categories (P-interaction = 0.97), including those at low risk (hazard ratio [HR] 0.54, 95% CI 0.38-0.77). Risks for categorical eGFR reductions (≥57% [in those with baseline eGFR ≥60 mL/min/1.73 m2], ≥50%, ≥40%, and ≥30%) were lower with dapagliflozin (HRs 0.52, 0.57, 0.55, and 0.70, respectively; P < 0.05). Slopes of eGFR decline favored dapagliflozin across KDIGO risk categories, including the low KDIGO risk (between-arm differences of 0.87 [chronic] and 0.55 [total] mL/min/1.73 m2/year; P < 0.0001).<h4>Conclusions</h4>Dapagliflozin mitigated kidney function decline in patients with T2D at high cardiovascular risk, including those with low KDIGO risk, suggesting a role of dapagliflozin in the early prevention of diabetic kidney disease.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Humans, Diabetic Nephropathies, Myocardial Infarction, Diabetes Mellitus, Type 2, Sodium, Benzhydryl Compounds, Glucosides, Glucose, Glomerular Filtration Rate, Sodium-Glucose Transporter 2 Inhibitors |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 25 Oct 2022 16:12 |
| Last Modified: | 06 Dec 2024 20:30 |
| DOI: | 10.2337/dc22-0382 |
| Open Access URL: | https://diabetesjournals.org/care/article/45/10/23... |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3165749 |
Altmetric
Altmetric
